| Name | Title | Contact Details |
|---|---|---|
Tom Dubensky |
Chief Executive Officer | Profile |
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company`s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination with platinum-doublet + bevacizumab compared to platinum-doublet + bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux` discovery and development efforts revolves around the company`s proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
TissueVision Inc. (TVI) is a multi-disciplinary life sciences company offering 3D tissue imaging and analysis solutions for the research market. Our powerful Serial Two-Photon Plus (STP²) platform features stunning high-resolution multispectral datasets and analysis pipelines that create reliable 3D tissue models. The indexed histological sections produced during the STP² process can be further investigated with secondary analyses that run the gamut from standard histological stains to advanced spatial genomics. The final result is rich, multiplexed 3D models that deliver actionable and quantitative results. TVI provides project design, GLP-like documentation, including full protocol and report generation, and quality control review measures of all study-related materials. TVI is a solution provider to help answer research questions in a variety of therapeutic areas, including neuroscience, cancer, neurodegeneration, ophthalmology, and dermatology.
Microbion is a clinical stage biopharmaceutical company. Microbion is developing MBN-101 as the first product in the bismuth-thiol class for the treatment of resistant and difficult to treat infections. MBN-101 has broad spectrum, anti-bacterial efficacy against a broad range of pathogens, including multiple priority pathogens or “superbugs”. In addition to anti-bacterial efficacy, MBN-101 also has highly advantageous and product-differentiating capability to prevent and eradicate microbial biofilms. The dual action from this first in class product provides a novel clinical approach to treating infections. Their effectiveness against MRSA, MDR TB, CRE, VRE, and other antibiotic resistant pathogens highlights their potential to provide solutions to the dramatic and alarming increase in global antibiotic resistance.
IU Health is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Xenobiotic Labs Inc is a Plainsboro, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.